Antimycobacterial activities of novel fluoroquinolones

Biomedicine and Pharmacotherapy

Volumn 63, Issue 1, 2009, Pages 27-35

  Senthilkumar, Palaniappan ^a   Dinakaran, Murugesan ^a   Yogeeswari, Perumal ^a   China, Arnab ^b   Nagaraja, Valakunja ^b   Sriram, Dharmarajan ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Antimycobacterial activity; Antitubercular activity; DNA gyrase inhibitors; Fluoroquinolones; Quinolones

Indexed keywords

1 (2,4 DIFLUOROPHENYL) 1,4 DIHYDRO 6 FLUORO 7 AMINO 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 1 (CYCLOPROPYL) 1,4 DIHYDRO 6 FLUORO 7 AMINO 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 1 (TERT BUTYL) 1,4 DIHYDRO 6 FLUORO 7 AMINO 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 7 [3 (DIETHYLCARBAMOYL)PIPERIDIN 1 YL] 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 4 OXOQUINOLINE 3 CARBOXYLIC ACID; DNA TOPOISOMERASE (ATP HYDROLYSING); GATIFLOXACIN; GYRASE INHIBITOR; ISONIAZID; LOMEFLOXACIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHOTOTOXICITY; PRIORITY JOURNAL; SPLEEN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTITUBERCULAR AGENTS; DERMATITIS, PHOTOTOXIC; DNA GYRASE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FLUOROQUINOLONES; MICE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS;

EID: 58049155418     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.10.004     Document Type: Article

References (22)

1. Williams B.G., and Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 301 (2003) 1535-1537
2. Corbett E.L., Watt C.J., Catherine J., Walker N., Maher D., Williams B.G., et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163 (2003) 1009-1021
3. Zignol M., Hosseini M.S., Wright A., Lambregts-van W.C., Nunn P., Watt C.J., et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 194 (2006) 479-485
4. Duncan K., and Barry C.E. Prospects for new antitubercular drugs. Curr Opin Microbiol 7 (2004) 1-6
5. Sato K., Tomioka H., Sano C., Shimizu T., Sano K., Ogasawara K., et al. Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. J Antimicrob Chemother 52 (2003) 199-203
6. Mitscher L.A. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem Rev 105 (2005) 559-592
7. Renau T.E., Sanchez J.P., Gage J.W., Dever J.A., Shapiro M.A., Gracheck S.J., et al. Structure-activity relationships of the quinolone antibacterials against Mycobacteria: effect of structural changes at N-1 and C-7. J Med Chem 39 (1996) 729-735
8. Anquetin G., Greiner J., Mahmoudi N., Santillana-Hayat M., Gozalbes R., Farhati K., et al. Design, synthesis and activity against Toxoplasma gondii, Plasmodium spp., and Mycobacterium tuberculosis of new 6-fluoroquinolones. Eur J Med Chem 41 (2006) 1478-1493
9. Sriram D., Yogeeswari P., Basha J.S., Radha D.R., and Nagaraja V. Synthesis and antimycobacterial evaluation of various 7-substituted ciprofloxacin derivatives. Bioorg Med Chem 13 (2005) 5774-5778
10. Sriram D., Aubry A., Yogeeswari P., and Fisher L.M. Gatifloxacin derivatives: Synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase. Bioorg Med Chem Lett 16 (2006) 2982-2985
11. Chu D.T.W., Fernandes P.B., Claiborne A.K., Pihuleac E., Nordeen C.W., Maleczka R.E., et al. Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents. J Med Chem 28 (1985) 1558-1564
12. National Committee for Clinical Laboratory Standards. Antimycobacterial susceptibility testing for Mycobacterium tuberculosis. Proposed standard M24-T (1995), National Committee for Clinical Laboratory Standards, Villanova, PA
13. Gundersen L.L., Nissen-Meyer J., and Spilsberg B. Synthesis and antimycobacterial activity of 6-arylpurines: The requirements for the N-9 substituent in active antimycobacterial purines. J Med Chem 45 (2002) 1383-1386
14. Manjunatha U.H., Dalal M., Chatterji M., Radha D.R., Visweswariah S.S., and Nagaraja V. Functional characterization of mycobacterial DNA gyrase: an efficient decatenase. Nucleic Acids Res 30 (2002) 2144-2152
15. Mayne T.N., Johnson N.J., Kluwe W.M., Lencoski D.L., and Polzer R.J. A study of the phototoxic potential of trovafloxacin in BALB/c mice. J Antimicrob Chemother 39 (1997) 67-73
16. Nikaido H., and Thanassi D.G. Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples. Antimicrob Agents Chemother 37 (1993) 1393-1399
17. Shen L.L. Molecular mechanism of DNA gyrase inhibition by quinolone antibacterials. Adv Pharmacol 29 (1994) 285-304
18. Levine C.H., Hiasa A., and Marians K.J. DNA gyrase and topoisomerase IV: Biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim Biophys Acta 1400 (1998) 29-43
19. Manjunatha U.H., Madhusudan K., Visweswariah S.S., and Nagaraja V. Structural heterogeneity in DNA gyrases from Gram-positive and Gram-negative bacteria. Curr Sci 79 (2000) 968-974
20. Ferguson J., Walker E.M., and Johnson B.E. Quinolone antibiotic-induced phototoxicity. Br J Dermatol 120 (1989) 291-295
21. Domagala J.M. Structure-activity and structure-side effect relationships for the quinolone antibacterials. J Antimicrob Chemother 33 (1994) 685-706
22. Takayama S., Hirohashi M., Kato M., and Shimada H. Toxicity of quinolone antimicrobial agents. J Toxicol Environ Health 45 (1995) 1-45